Anastrozole (Arimidex) - Non-Steroidal Aromatase Inhibitor — Anabolic Steroids
Third-generation non-steroidal aromatase inhibitor FDA-approved for hormone receptor-positive breast cancer, widely used off-label in bodybuilding for estrogen management during anabolic steroid cycles.
Overview
Anastrozole (Arimidex) is a potent, selective, non-steroidal third-generation aromatase inhibitor that reversibly binds the CYP19 aromatase enzyme, reducing circulating estradiol levels by approximately 80-85% in postmenopausal women. The landmark ATAC trial (Arimidex, Tamoxifen, Alone or in Combination; n=9,366) demonstrated a 26% reduction in breast cancer recurrence compared to tamoxifen (HR 0.74) with superior tolerability in postmenopausal women with early-stage hormone receptor-positive breast cancer. FDA-approved in 1995 for breast cancer treatment. In men, anastrozole is used off-label to manage estradiol elevation during testosterone replacement therapy or anabolic steroid cycles, preventing gynecomastia and water retention. The compound suppresses estradiol in a dose-dependent fashion without affecting cortisol or aldosterone synthesis. Key concern in males is over-suppression of estradiol, which is essential for bone density, libido, lipid metabolism, and cardiovascular health. PMID: 11902316, 15570071, 20091174.
Indications
- Adjuvant treatment of postmenopausal women with HR+ early breast cancer (FDA-approved; ATAC trial)
- First-line treatment of advanced/metastatic breast cancer in postmenopausal women (FDA-approved)
- Estrogen management during testosterone replacement therapy in men (off-label)
- Gynecomastia prevention during anabolic steroid cycles (off-label, bodybuilding use)
- Pubertal gynecomastia in adolescent males (off-label; limited evidence)
Mechanism of Action
CYP19 aromatase catalyzes the conversion of androstenedione and testosterone to estrone and estradiol in adipose tissue, breast tissue, ovaries, and brain
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Anastrozole (Arimidex) | 1 mg | Once daily | FDA-approved dose for breast cancer; ATAC trial dose; take with or without food |
| Anastrozole | 0.5 mg | Every other day (EOD) | Common off-label dose for estrogen management during TRT or mild AAS cycles |
| Anastrozole | 1 mg | Every other day (EOD) | Off-label dose for heavy aromatizing AAS cycles; higher risk of estradiol over-suppression |
| Anastrozole | 0.25 mg | Every other day (EOD) | Lowest dose for sensitive individuals on TRT; titrate based on E2 levels |
Evidence Grade
GRADE A
Safety & Contraindications
- Accelerated bone mineral density loss: ATAC trial showed increased fracture risk (11% vs 7.7% with tamoxifen); bone density monitoring essential
- Arthralgia and musculoskeletal symptoms in 35% of patients (breast cancer studies); dose-dependent and may limit adherence
- Over-suppression of estradiol in males can cause fatigue, joint pain, decreased libido, erectile dysfunction, and accelerated bone loss
- Adverse lipid effects: non-steroidal AIs may worsen lipid profiles (increase total cholesterol and LDL) unlike tamoxifen which improves lipids
- Contraindicated in premenopausal women unless with ovarian suppression; not for use during pregnancy (teratogenic)
- Drug interactions: potent CYP3A4 substrates; avoid concurrent tamoxifen (reduces anastrozole levels by 27%)